Revelation Biosciences Stock Price, News & Analysis

Revelation Biosciences (NASDAQ: REVB) has completed patient dosing in its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study. The trial evaluated escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).

The study successfully enrolled 5 cohorts across 3 U.S. clinics. Multiple data sets are expected in Q3 2025, including safety parameters, hematologic changes, inflammatory response evaluation, and biomarker activity. The company plans to engage with the FDA to discuss future clinical development and approval pathways later in 2025.

Revelation Biosciences (NASDAQ: REVB) has announced a 1-for-3 reverse stock split effective July 7, 2025, following stockholder approval on June 23, 2025. The reverse split aims to increase the stock price to regain compliance with Nasdaq Capital Market's minimum bid listing requirements.

The company will maintain its trading symbol "REVB" with a new CUSIP number 76135L705. Proportionate adjustments will be made to conversion and exercise prices of warrants, restricted stock units, stock options, and shares under equity incentive plans. Additionally, REVB announced that enrollment for its PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete this month, with topline data anticipated shortly after.

Stockholders will see their shares automatically converted, with fractional shares rounded down. No action is required from registered stockholders or those holding shares through brokers.

Revelation Biosciences (NASDAQ: REVB) has closed its previously announced public offering, raising $4 million in gross proceeds. The offering included 3,640,000 shares of common stock (or equivalents) and warrants to purchase up to 14,560,000 shares at $1.10 per share. The warrants have a five-year expiration term from the initial exercise date. Roth Capital Partners served as the sole placement agent. The company plans to use the proceeds for product development, including completing their ongoing Phase 1b clinical study, manufacturing clinical drug supply, conducting preclinical work for multiple indications, developing other products, and funding working capital and general corporate purposes.

Revelation Biosciences (NASDAQ: REVB) has announced a $4 million public offering, pricing 3,640,000 shares of common stock at $1.10 per share. The offering includes warrants to purchase up to 14,560,000 additional shares, also at $1.10 per share, exercisable for 5 years after stockholder approval. Roth Capital Partners is serving as the sole placement agent. The proceeds will fund: (1) completion of ongoing Phase 1b clinical study, (2) clinical drug supply manufacturing, (3) preclinical work for multiple indications, (4) development of other products/therapies, and (5) working capital. The offering is expected to close around May 29, 2025, subject to customary conditions.

Revelation Biosciences (NASDAQ: REVB) announced the retirement of George F. Tidmarsh, MD, PhD from its Board of Directors. Dr. Tidmarsh, who served on the board for 5 years, is stepping down to avoid potential conflicts of interest as he takes on new responsibilities working with US governmental agencies in his role as Adjunct Professor of Pediatrics and Neonatology at Stanford University School of Medicine. CEO James Rolke expressed gratitude for Dr. Tidmarsh's guidance and support during his tenure.

Revelation Biosciences (NASDAQ: REVB) reported its Q1 2025 financial results and corporate updates. The company highlighted progress with its Gemini program, including a new indication for severe burn patients and data showing inflammation attenuation in peripheral blood mononuclear cells. Revelation also completed first patient dosing in the PRIME Phase 1b Clinical Study of Gemini in CKD patients, with topline data expected in summer 2025. Financially, REVB reported cash and cash equivalents of $3.7 million as of March 31, 2025, down from $6.5 million at year-end 2024. The company's Q1 2025 net loss was $2.1 million ($(2.11) per share), compared to $2.7 million ($(39.37) per share) in Q1 2024. Current cash runway extends through June 2025, with quarterly cash burn of $2.8 million remaining stable year-over-year.

Revelation Biosciences (NASDAQ: REVB) has announced plans to develop its Gemini Platform for preventing infections in severe burn patients requiring hospitalization (GEM-PBI program). This initiative builds upon their existing work on preventing post-surgical infections (GEM-PSI program).

The company is collaborating with Vanderbilt University, from whom they previously licensed the patent family. Dr. Julia Bohannon, Associate Professor at Vanderbilt, reported that Gemini's clinical biomarker activity aligns with their preclinical infection burn models. Research shows the treatment reduces pseudomonas lung infection severity and duration while lowering overall inflammation levels.

CEO James Rolke emphasized that this expansion into burn patient care complements Revelation's existing work, noting that the Gemini-PBI program may present new opportunities in regulatory approval, development, and funding.

Revelation Biosciences (NASDAQ: REVB) announced positive results from a study showing that Gemini effectively reduces inflammation in human peripheral blood mononuclear cells (PBMCs). The study demonstrated that Gemini-primed PBMCs, when exposed to inflammatory promoters HMGB-1 and LPS, showed significantly decreased proinflammatory cytokines and increased anti-inflammatory cytokines compared to placebo.

The company is currently conducting a Phase 1b PRIME clinical study in patients with Stage 3 and 4 Chronic Kidney Disease (CKD), with top-line data expected by mid 2025. This data will include safety, tolerability, and cellular-level protection assessment, supporting future development of GEM-CKD, GEM-AKI, and GEM-PSI programs.

Revelation Biosciences (NASDAQ: REVB), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, has announced its participation in the 37th Annual Roth Conference. James Rolke, the company's Chief Executive Officer, will engage in a fireside chat scheduled for Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.

The event will be accessible through a live webcast and will subsequently be available for viewing in the Investors section of Revelation's website at www.RevBiosciences.com. Interested investors can arrange meetings with the management team through their Roth representatives.